Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Shanxi Dayu Biological Functions Co (BJSE:920970) EBITDA Margin % Explanation
EBITDA Margin % is the ratio of EBITDA divided by net sales or Revenue. It is an performance metric measuring company's operating profitability. EBITDA Margin takes depreciation and amortization, interest expense and tax into account, which makes it easy to compare the relative profitability of companies of different sizes in the same industry.
Shanxi Dayu Biological Functions Co EBITDA Margin % Related Terms
Shanxi Dayu Biological Functions Co EBITDA Margin % Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Shanxi Dayu Biological Functions Co EBITDA Margin % Chart
BJSE:920970 vs VRTX, REGN, MRNA: EBITDA Margin % Comparison
For the Biotechnology subindustry, Shanxi Dayu Biological Functions Co's EBITDA Margin %, along with its competitors' market caps and EBITDA Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Shanxi Dayu Biological Functions Co EBITDA Margin % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Shanxi Dayu Biological Functions Co's EBITDA Margin % distribution charts can be found below:
* The bar in red indicates where Shanxi Dayu Biological Functions Co's EBITDA Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Shanxi Dayu Biological Functions Co (BJSE:920970) has a EBITDA Margin % of -20.13% as of Jun. 2026. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Shanxi Dayu Biological Functions Co and its competitors. According to the industry distribution chart, Shanxi Dayu Biological Functions Co ranks #405 out of 945 companies in the Biotechnology industry, placing it in the top 42.9%.
Is Shanxi Dayu Biological Functions Co's EBITDA Margin % too high?
Shanxi Dayu Biological Functions Co's current EBITDA Margin % is -20.13%. Based on the distribution chart, Shanxi Dayu Biological Functions Co ranks #405 out of 945 companies in the Biotechnology industry, which is above the industry midpoint. Overall, Shanxi Dayu Biological Functions Co has a GF Score™ of 66/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Shanxi Dayu Biological Functions Co's EBITDA Margin % compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Shanxi Dayu Biological Functions Co ranks #405 out of 945 companies for EBITDA Margin %. This puts Shanxi Dayu Biological Functions Co in the upper half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBITDA Margin % for a Biotechnology company?
A good EBITDA Margin % depends on the Biotechnology industry context. However, EBITDA Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBITDA Margin % mean?
A high EBITDA Margin % can signal that a stock is expensive relative to its fundamentals. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Shanxi Dayu Biological Functions Co and its competitors. Shanxi Dayu Biological Functions Co's current EBITDA Margin % is -20.13%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Shanxi Dayu Biological Functions Co stock overvalued right now?
Based on GuruFocus' analysis, Shanxi Dayu Biological Functions Co (BJSE:920970) is currently considered Modestly Undervalued. The stock's GF Value™ is ¥7.30, compared to a current price of ¥6.58 — trading 9.9% below its estimated fair value. The current EBITDA Margin % is -20.13%. Shanxi Dayu Biological Functions Co's overall GF Score™ is 66/100 with 8 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBITDA Margin % calculated?
EBITDA Margin % is calculated from a company's financial statements. For Shanxi Dayu Biological Functions Co (BJSE:920970), the current EBITDA Margin % is -20.13% as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Shanxi Dayu Biological Functions Co (BJSE:920970) Overvalued in 2026?
Based on GuruFocus' analysis, Shanxi Dayu Biological Functions Co stock appears to be undervalued.
The current stock price of ¥6.58 is trading 9.9% below its estimated GF Value™ of ¥7.30.
GuruFocus considers Shanxi Dayu Biological Functions Co to be Modestly Undervalued.
Key valuation signals for BJSE:920970:
EBITDA Margin %: -20.13%
GF Value™: ¥7.30 vs. price of ¥6.58 (9.9% below fair value)
No single metric tells the full story. See the BJSE:920970 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Shanxi Dayu Biological Functions Co Ltd engages in the research and development of bioengineering technology and product application. Its main products are probiotics, enzyme preparations, fermented traditional Chinese medicine, biological preparations, and veterinary preparations.
66GF Score
Get the complete analysis for BJSE:920970
EBITDA Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
BJSE:920970 has been successfully added to your 
